Results 81 to 90 of about 5,288 (183)
HM71224, a selective Bruton’s tyrosine kinase inhibitor, attenuates the development of murine lupus
Arthritis Research & Therapy, 2017 Background Systemic lupus erythematosus (SLE) is associated with B cell hyperactivity, and lupus nephritis (LN), in particular, is promoted by the production of autoantibodies and immune complex deposition.
Yu-Yon Kim +8 more
doaj +1 more source
Targetable Vulnerabilities in MYC‐Driven B Cell Lymphomas Resistant to BCR Extinction
Hematological Oncology, Volume 44, Issue 2, March 2026.ABSTRACT Polatuzumab vedotin, an antibody‐drug conjugate (ADC) targeting the B cell receptor (BCR) signaling subunit CD79B, has recently entered frontline therapy for diffuse large B cell lymphoma (DLBCL) and high‐grade B cell lymphoma (HGBCL), achieving encouraging clinical results. However, MYC‐driven B cell lymphomas, particularly HGBCL with MYC and
Silvia Brambillasca +15 more
wiley +1 more source
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
eLife, 2020 Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site.
Raji E Joseph +5 more
doaj +1 more source
The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]
, 2019 Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core
The bone marrow microenvironment – Home of the leukemic blasts [PDF]
, 2017 Acute Myeloid Leukaemia (AML) is a genetically, biologically and clinically heterogeneous set of diseases, which are characterised by an increased growth of abnormal myeloid progenitor cells within the bone marrow (BM).
Bowles, Kristian M +3 more
core +1 more source
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies
European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino +10 more
wiley +1 more source
The X Factor in Immunity: Sex Differences Shaped by the X Chromosome
Immunological Reviews, Volume 338, Issue 1, March 2026.ABSTRACT There are sex differences with immune responses where females exhibit stronger immune responses compared to males. Both sex hormones and sex chromosome differences between males and females contribute to the observed sex differences with innate and adaptive immune cell composition and function.
Katherine B. Radovanovic +2 more
wiley +1 more source
Bruton’s tyrosine kinase signaling in health and disease:a molecular perspective [PDF]
, 2021 In this thesis, we studied the role of Bruton's tyrosine kinase (Btk) in B cells. We specifically investigated the role of different receptor signaling pathways in which Btk is involved and the contribution of Btk signaling to the development of leukemia
Rip, Jasper
core
Polymethoxylated N‐Carboranyl Isoquinolinones: A New Scaffold for ABCG2 Inhibitors
ChemMedChem, Volume 21, Issue 3, 12 February 2026.Combinations of a boron‐based clusters (carborane) and polymethoxy group patterns are crucial to overcome ABCG2‐mediated multidrug resistance in cancer cells. (Created in BioRender. Kuhnert, L. (2025) https://BioRender.com/h4cnh5m). ABCG2‐mediated multidrug resistance (MDR) is a major challenge among chemotherapeutic treatments of colon, pancreatic ...
Lydia Kuhnert +5 more
wiley +1 more source